{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:27:39Z","timestamp":1793388459288,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00942-9","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:02:27Z","timestamp":1724140947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer\u2019s disease in 3xTg mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Xuejian","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-5235","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3068-3805","authenticated-orcid":false,"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"942_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"942_CR5","first-page":"534","volume":"8","author":"MB Usman","year":"2021","unstructured":"Usman, M. B. et al. Immunotherapy for Alzheimer\u2019s disease: current scenario and future perspectives. J. Prev. Alzheimers Dis. 8, 534\u2013551 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"942_CR6","doi-asserted-by":"publisher","first-page":"101496","DOI":"10.1016\/j.arr.2021.101496","volume":"72","author":"D Jeremic","year":"2021","unstructured":"Jeremic, D., Jim\u00e9nez-D\u00edaz, L. & Navarro-L\u00f3pez, J. D. Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: a systematic review. Ageing Res. Rev. 72, 101496 (2021).","journal-title":"Ageing Res. Rev."},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.ebiom.2023.104665","volume":"94","author":"HJ Yu","year":"2023","unstructured":"Yu, H. J. et al. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine 94, 104665 (2023).","journal-title":"EBioMedicine"},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"942_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40478-019-0823-2","volume":"7","author":"E Ercan-Herbst","year":"2019","unstructured":"Ercan-Herbst, E. et al. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer\u2019s disease brain. Acta Neuropathol. Commun. 7, 192 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"e75025","DOI":"10.1371\/journal.pone.0075025","volume":"8","author":"V Duka","year":"2013","unstructured":"Duka, V. et al. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer\u2019s diseases. PLoS ONE 8, e75025 (2013).","journal-title":"PLoS ONE"},{"key":"942_CR11","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain 140, 3286\u20133300 (2017).","journal-title":"Brain"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/alz.12453","volume":"18","author":"BP Imbimbo","year":"2022","unstructured":"Imbimbo, B. P. et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 18, 1008\u20131037 (2022).","journal-title":"Alzheimers Dement."},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff, R. M. How neuroinflammation contributes to neurodegeneration. Science 353, 777\u2013783 (2016).","journal-title":"Science"},{"key":"942_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman, A. et al. Transcriptional signature in microglia associated with A\u03b2 plaque phagocytosis. Nat. Commun. 12, 3015 (2021).","journal-title":"Nat. Commun."},{"key":"942_CR15","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice. J. Neurosci. 28, 8354\u20138360 (2008).","journal-title":"J. Neurosci."},{"key":"942_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1309-z","volume":"15","author":"SC Hopp","year":"2018","unstructured":"Hopp, S. C. et al. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer\u2019s disease. J. Neuroinflammation 15, 269 (2018).","journal-title":"J. Neuroinflammation"},{"key":"942_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.aat0473","volume":"362","author":"NJ Allen","year":"2018","unstructured":"Allen, N. J. & Lyons, D. A. Glia as architects of central nervous system formation and function. Science 362, 181\u2013185 (2018).","journal-title":"Science"},{"key":"942_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s42003-020-0792-9","volume":"3","author":"C Hughes","year":"2020","unstructured":"Hughes, C. et al. Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death. Commun. Biol. 3, 79 (2020).","journal-title":"Commun. Biol."},{"key":"942_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-150","volume":"8","author":"J Zhao","year":"2011","unstructured":"Zhao, J., O\u2019Connor, T. & Vassar, R. The contribution of activated astrocytes to A\u03b2 production: implications for Alzheimer\u2019s disease pathogenesis. J. Neuroinflammation 8, 150 (2011).","journal-title":"J. Neuroinflammation"},{"key":"942_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"942_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/JAD-2009-0933","volume":"16","author":"P Hernandez","year":"2009","unstructured":"Hernandez, P. et al. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25\u201335): involvement of lipid rafts. J. Alzheimers Dis. 16, 149\u2013156 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"942_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2353\/ajpath.2008.070904","volume":"172","author":"D Terwel","year":"2008","unstructured":"Terwel, D. et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172, 786\u2013798 (2008).","journal-title":"Am. J. Pathol."},{"key":"942_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","volume":"31","author":"ED Roberson","year":"2011","unstructured":"Roberson, E. D. et al. Amyloid-\u03b2\/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease. J. Neurosci. 31, 700\u2013711 (2011).","journal-title":"J. Neurosci."},{"key":"942_CR24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Interaction between A\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int. J. Biol. Sci. 17, 2181\u20132192 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.25395","volume":"85","author":"RA Sperling","year":"2019","unstructured":"Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181\u2013193 (2019).","journal-title":"Ann. Neurol."},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"942_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","volume":"79","author":"M Timmers","year":"2019","unstructured":"Timmers, M. et al. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer\u2019s disease. Neurobiol. Aging 79, 131\u2013141 (2019).","journal-title":"Neurobiol. Aging"},{"key":"942_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep41041","volume":"7","author":"L Fu","year":"2017","unstructured":"Fu, L. et al. Norovirus P particle-based active A\u03b2 immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer\u2019s disease. Sci. Rep. 7, 41041 (2017).","journal-title":"Sci. Rep."},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-020-00416-z","volume":"6","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer\u2019s disease. Signal Transduct. Target. Ther. 6, 61 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"942_CR30","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1016\/j.cell.2022.09.002","volume":"185","author":"Y Yan","year":"2022","unstructured":"Yan, Y. et al. X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women. Cell 185, 3913\u20133930.e19 (2022).","journal-title":"Cell"},{"key":"942_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157\u2013172 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"942_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-019-0556-2","volume":"11","author":"H Davtyan","year":"2019","unstructured":"Davtyan, H. et al. Testing a MultiTEP-based combination vaccine to reduce A\u03b2 and tau pathology in Tau22\/5xFAD bigenic mice. Alzheimer\u2019s Res. Ther. 11, 107 (2019).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"942_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17313-1","volume":"7","author":"H Rajamohamedsait","year":"2017","unstructured":"Rajamohamedsait, H. et al. Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid-\u03b2 pathologies in 3xTg mice. Sci. Rep. 7, 17034 (2017).","journal-title":"Sci. Rep."},{"key":"942_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","volume":"9","author":"C-l Dai","year":"2017","unstructured":"Dai, C.-l et al. Tau passive immunization inhibits not only tau but also A\u03b2 pathology. Alzheimer\u2019s Res. Ther. 9, 1 (2017).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"942_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep28912","volume":"6","author":"H Davtyan","year":"2016","unstructured":"Davtyan, H. et al. Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A\u03b2 pathological molecules. Sci. Rep. 6, 28912 (2016).","journal-title":"Sci. Rep."},{"key":"942_CR36","doi-asserted-by":"publisher","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","volume":"288","author":"EE Congdon","year":"2013","unstructured":"Congdon, E. E. et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fc\u03b3 receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288, 35452\u201335465 (2013).","journal-title":"J. Biol. Chem."},{"key":"942_CR37","doi-asserted-by":"publisher","first-page":"33081","DOI":"10.1074\/jbc.M113.494922","volume":"288","author":"J Gu","year":"2013","unstructured":"Gu, J., Congdon, E. E. & Sigurdsson, E. M. Two novel Tau antibodies targeting the 396\/404 region are primarily taken up by neurons and reduce Tau protein pathology. J. Biol. Chem. 288, 33081\u201333095 (2013).","journal-title":"J. Biol. Chem."},{"key":"942_CR38","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, P., Deng, Y. & Sigurdsson, E. M. Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front. Psychiatry 2, 59 (2011).","DOI":"10.3389\/fpsyt.2011.00059"},{"key":"942_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3233\/HAB-160306","volume":"25","author":"JM Finke","year":"2017","unstructured":"Finke, J. M. & Banks, W. A. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer\u2019s disease immunotherapy. Hum. Antibodies 25, 131\u2013146 (2017).","journal-title":"Hum. Antibodies"},{"key":"942_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"942_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky, V. et al. Safety and tolerability of BAN2401-a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimers Res. Ther. 8, 14 (2016).","journal-title":"Alzheimers Res. Ther."},{"key":"942_CR42","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos, R. B. et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease. Science 295, 2264\u20132267 (2002).","journal-title":"Science"},{"key":"942_CR43","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C. et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).","journal-title":"PLoS Biol."},{"key":"942_CR44","doi-asserted-by":"crossref","unstructured":"Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. 1787 (2010).","DOI":"10.3791\/1787-v"},{"key":"942_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01749-w","volume":"17","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3\u03b1 in tau P301S mouse model of Alzheimer\u2019s disease. J. Neuroinflammation 17, 72 (2020).","journal-title":"J. Neuroinflammation"},{"key":"942_CR46","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.neuron.2023.05.006","volume":"111","author":"PW Sheehan","year":"2023","unstructured":"Sheehan, P. W. et al. An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathology. Neuron 111, 2383\u20132398.e7 (2023).","journal-title":"Neuron"},{"key":"942_CR47","doi-asserted-by":"crossref","unstructured":"Young, K. & Morrison, H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using imageJ. J. Vis. Exp. 57648 (2018).","DOI":"10.3791\/57648-v"},{"key":"942_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13581-z","volume":"7","author":"H Morrison","year":"2017","unstructured":"Morrison, H. et al. Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury. Sci. Rep. 7, 13211 (2017).","journal-title":"Sci. Rep."},{"key":"942_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.neuron.2014.11.020","volume":"85","author":"P Chakrabarty","year":"2015","unstructured":"Chakrabarty, P. et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519\u2013533 (2015).","journal-title":"Neuron"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00942-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00942-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00942-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:03:56Z","timestamp":1724141036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00942-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00942-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3927092\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}